The coronavirus outbreak in recent times has created a terrific pandemic situation in the universe. We aim to identify the specific domain in the viral particle responsible for binding into the host cell and for finding any anti-viral... more
The coronavirus outbreak in recent times has created a terrific pandemic situation in the universe. We aim to identify the specific domain in the viral particle responsible for binding into the host cell and for finding any anti-viral drug that could inhibit the binding interaction. Using pharmacophore-based drug modelling for drug molecule that can inhibit the spike protein interaction is targeted. Spike protein of a viral body (SARS-CoV-2) represents a structure that acts as the ligand that binds with the host, made up of several repeats of Beta sheets acts as the substrate-binding domain part. The anti-viral drug or the antibody inhibit the interaction between the spike and the receptor, are predicted via receptor-ligand interaction of the desired or predictable drug molecule. Common and trusted anti-viral strategies directed to S-protein consist of mitigation of host recognition by acting on S1-RBD (Spike Protein Receptor Binding Domain) coupled with inhibition of fusion process by acting at the level of S2 sub-unit has been explored. Drugs like Favipiravir and Barcitinib are in use to reduce viral entry in the host cells, along with several developing vaccines.
After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the outbreak of coronavirus disease 2019 (COVID-19) commenced across the world. Understanding the Immunopathogenesis of COVID-19 is essential for... more
After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the outbreak of coronavirus disease 2019 (COVID-19) commenced across the world. Understanding the Immunopathogenesis of COVID-19 is essential for interrupting viral infectivity and preventing aberrant immune responses before a vaccine can be developed. In this review, we provide the latest insights into the roles of angiotensinconverting enzyme II (ACE2) and Ang II receptor-1 (AT1-R) in
Actualmente nos encontramos en una pandemia mundial causada por el coronavirus 2019 o COVID-19, presentando diferentes desafíos para el sistema de salud debido a que no se cuenta aún con alguna vacuna ni con un tratamiento que haya... more
Actualmente nos encontramos en una pandemia mundial causada por el coronavirus 2019 o COVID-19, presentando diferentes desafíos para el sistema de salud debido a que no se cuenta aún con alguna vacuna ni con un tratamiento que haya demostrado su eficacia en totalidad, siendo el manejo actual preventivo y de soporte. Por lo que, en esta revisión se estudiará a los fármacos antirreumáticos más resaltantes que tengan un probable efecto farmacológico, como son la hidroxicloroquina, el tocilizumab, el anakinra y el baricitinib, frente al COVID-19. Se espera que brinde apoyo para futuros tratamientos e investigaciones sobre la enfermedad.